AbbVie, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 50K
- Market Cap
- -
- Website
- http://www.abbvie.com
Clinical Trials
4
Active:4
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
13
SFDA:12
NMPA:1
Drug Approvals
Lopinavir/Ritonavir Oral Solution
- Product Name
- 克力芝
- Approval Number
- 国药准字HJ20130773
- Approval Date
- Jun 7, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)No trials found
News
Delhi High Court Upholds Strict Patent Amendment Rules in Two Key Pharmaceutical Cases
The Delhi High Court upheld patent rejections in two separate pharmaceutical cases, reinforcing strict disclosure requirements and amendment limitations under Indian patent law.
Global Cerebral Palsy Clinical Trial Landscape Assessed in New 2024 Review
A new report provides an overview of the global clinical trial landscape for cerebral palsy, including trial numbers and enrollment trends.
Cerevel Therapeutics Advances Emraclidine Development for Alzheimer's-Related Dementia and Psychosis
Cerevel Therapeutics is developing Emraclidine (CVL-231), a novel oral M4 muscarinic receptor positive allosteric modulator, for treating dementia and psychosis in Alzheimer's disease.